Evidence-based clinical practice guidelines for peptic ulcer disease 2026.

Authors

Mitsushige Sugimoto, Tomoari Kamada, Masanori Ito, Junichi Iwamoto, Tadayoshi Okimoto, Shoko Ono, Takeshi Kanno, Toshimi Chiba, Kengo Tokunaga, Sachiyo Nomura, Takahisa Murao, Toshio Watanabe, Daisuke Asaoka, Eri Iwata, Ting Wang, Hideki Ono, Ryo Katsumata, Satoshi Kikuchi, Naoki Konishi, Satoshi Sato, Aya Sunago, Hiromi Sekiguchi, Hourin Cho, Daisuke Chinda, Osamu Dohi, Akinobu Nakata, Akira Higashimori, Yuka Hirashita, Keigo Misawa, Kazuhiro Mizukami, Daisuke Miyamori, Junko Mukohyama, Hideki Mori, Shuhei Yoshida, Jun Watanabe, Kiichi Satoh, Yuji Mizokami, Atsushi Takagi, Yoshifumi Takeyama, Susumu Eguchi, Sumio Watanabe, Hajime Isomoto, Takao Itoi, Satoshi Mochida

Published in

Journal of gastroenterology. Aug 24, 2026. Epub Aug 24, 2026.

Abstract

In 2026, the fourth edition of the evidence-based clinical practice guidelines for peptic ulcer disease by the Japanese Society of Gastroenterology (JSGE) was revised. These revised guidelines cover epidemiology, hemorrhagic peptic ulcers, Helicobacter pylori eradication therapy, non-eradication therapy, drug-induced ulcers, non-H. pylori, and nonsteroidal anti-inflammatory drug (NSAID) ulcers, remnant gastric ulcers, surgical treatment, and conservative therapy for perforation and stenosis. Although H. pylori infection and NSAIDs use remain two major causes of peptic ulcers, the prevalence and mortality rates of peptic ulcer have been declining due to the widespread use of eradication therapy and development of potent acid-inhibitory drugs in recent years. However, an increasing trend in idiopathic ulcers and ulcers caused by non-H. pylori Helicobacter (NHPH) infection has attracted attention. In this revised edition, therapeutic algorithms for the treatment of peptic ulcers based on H. pylori infection, low-dose aspirin (LDA) or NSAID use, ulcer history, and ulcer complications (e.g., hemorrhage) remain largely unchanged. This edition shows options for H. pylori eradication in various situations compared with the previous edition, and recommends the most effective regimens, regardless of Japanese insurance coverage. In addition, a new flowchart outlining the eradication treatment process has been presented. Compared with the previous version, the main changes in pharmacological treatment have been made: due to its acid-inhibitory characteristics compared with proton pump inhibitors and increased evidence of its efficacy and safety, vonoprazan has now been selected as the first-line treatment for peptic ulcers and NSAID- and LDA-induced ulcers.

PMID:
42635735
Bibliographic data and abstract were imported from PubMed on 25 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.